ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
ENANTA PHARMACEUTICALS INC
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$11.41+0.31 (+2.79%)
Close on Oct 19, 2026
- Market cap
- $331.92M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
-130.7%−96.7 pts over 5 years
Net margin
-125.4%−95.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -3.4% | -8.8% | -11.8% | -8.6% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 8.6% | -7.9% | -84.6% | |
| Return on assets | 8.2% | -7.4% | -24.9% | |
| Current ratio | 29.43 | 18.08 | 4.21 | |
| Interest coverage | 685.4× | – | -11.1× | |
| Capex to revenue | 5.4% | 1.2% | 19.7% | |
| Diluted shares | 19M | 0M | 0M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Enanta Pharmaceuticals generated $355.97M from operations and spent $42.78M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$355.97M
Used
$42.78M
Capital expenditure$42.78M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-125.4%
×Asset turnover0.20×
×Equity multiplier3.40×
=Return on equity, FY2025-84.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -125.4% | 0.20× | 3.40× | -84.6% |
| FY2024 | -171.6% | 0.16× | 2.43× | -67.2% |
| FY2023 | -169.0% | 0.19× | 1.56× | -49.7% |
| FY2022 | -141.3% | 0.21× | 1.13× | -33.8% |
| FY2021 | -81.4% | 0.21× | 1.08× | -18.5% |
| FY2020 | -29.5% | 0.25× | 1.06× | -7.9% |
| FY2019 | 22.6% | 0.45× | 1.06× | 10.8% |
| FY2018 | 34.8% | 0.56× | 1.07× | 20.7% |
| FY2017 | 17.2% | 0.34× | 1.06× | 6.2% |
| FY2016 | 24.5% | 0.33× | 1.04× | 8.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$81.89M
- Cash generatingOperating cash flow above zero-$19.27M
- Return on assets improvedROA up on the prior year-25.1% → -21.7%
- Earnings backed by cashOperating cash flow above net income-$19.27M vs -$81.89M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose5.21 → 4.21
- No dilutionShare count did not rise0M → 0M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.15 → 0.17